The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
Where the revenue comes from
Fiscal 2025, as PLUS THERAPEUTICS, INC. reports it. History and quarterly detail are in the app.
- Grant$5.2M
Leadership changes
From PLUS THERAPEUTICS, INC.'s own filings, the day they're filed.
- Ronald A. Andrews · director · departureeff. 2026-03-20
- Kyle Guse · director · departureeff. 2025-04-18
- Norman LaFrance · Chief Medical Officer · departureeff. 2024-06-12
Latest filings
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-08-14
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-06-05
- 10-Q · Quarterly report2026-05-15
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about PLUS THERAPEUTICS, INC., every answer cited to the official filings🔒
- The Intelligence Brief — added when PLUS THERAPEUTICS, INC.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.